Changes and clinical significance of serum tumor markers in patients with non-small cell lung cancer before and after gefitinib targeted therapy / 中国医师杂志
Journal of Chinese Physician
; (12): 889-892, 2018.
Article
em Zh
| WPRIM
| ID: wpr-705921
Biblioteca responsável:
WPRO
ABSTRACT
Objective To investigate the changes and clinical significance of serum tumor markers in patients with non-small cell lung cancer before and after gefitinib targeted therapy.Methods 80 cases of non-small cell lung cancer patients in our hospital from June 2015 to May 2017 were divided into control group and observation group randomly,40 cases in each group.The control group were treated with docetaxel conventional chemotherapy,and the observation group were treated with gefitinib targeted therapy.The clinical treatment effect,changes of serum tumor markers cancer antigen125 (CA125),carcinoembryonic antigen (CEA),neuron specific enolase (NSE) and adverse reactions were observed and compared between the two groups before and after treatment.Results The effective rate and disease control rate of the observation group were higher than that in the control group,with statistically significant difference (P < 0.05).The levels of serum tumor markers CA125,CEA and NSE in the control group and the observation group before treatment were not significantly different (P > 0.05).After 1 months of treatment,the levels of serum tumor markers CA125,CEA and NSE in the two groups were all decreased,and the level of serum tumor markers,CA125,CEA and NSE in the observation group were lower than those in the control group,with statistically significant difference.The incidence of adverse reactions in the observation group was lower than that in the control group (P < 0.05),with statistically significant difference.Conclusions Gefitinib is effective in the treatment of non-small cell lung cancer.It reduces the level of serum tumor markers CA125,CEA,NSE,and reduces postoperative adverse reactions.It is worthy of clinical application.
Texto completo:
1
Índice:
WPRIM
Idioma:
Zh
Revista:
Journal of Chinese Physician
Ano de publicação:
2018
Tipo de documento:
Article